Cytokine storm in individuals with severe COVID-19 decreases endothelial cell antioxidant defense via Downregulation of the Nrf2 transcriptional factor.

Abstract

The cytokine storm in SARS-CoV-2 infection contributes to the onset of inflammation and target organ damage. The endothelium is a key player in COVID-19 pathophysiology and it is an important target for cytokines. Since cytokines trigger oxidative stress and negatively impact endothelial cell function, we sought to determine whether serum derived from severe COVID-19 individuals decreases endothelial cells' main antioxidant defense, i.e. the antioxidant transcriptional factor Nrf2. Human umbilical vein endothelial cells (HUVEC) were incubated with severe COVID-19 serum at different time points and the effects on redox balance and Nrf2 activity were determined. Serum from COVID-19 individuals increased oxidant species, as indicated by higher DHE oxidation, increased protein carbonylation and augmented mitochondrial reactive oxygen species (ROS) generation and dysfunction. COVID-19 serum, in comparison with serum from healthy individuals, induced cell death and diminished nitric oxide (NO) bioavailability. In parallel, Nrf2 nuclear accumulation and the expression of Nrf2-targeted genes were reduced in endothelial cells exposed to serum from COVID-19 individuals. Additionally, these cells exhibited higher expression of Bach-1, a negative regulator of Nrf2 that competes for DNA binding. All events were prevented by Tocilizumab, an IL-6 receptor blocker, indicating that IL-6 is key to the impairment of endothelial antioxidant defense. In conclusion, endothelial dysfunction related to SARS-Cov-2 infection is linked to an IL-6-dependent decrease in the endothelial antioxidant defense. Pharmacological activation of Nrf2 may decrease endothelial cell damage in individuals with severe COVID-19.